Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Wogonin
Cat. No.:
OB0225LY-0304
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Wogonin is a mTOR inhibitor with potential antitumor activity.
Synonym:
Vogonin; 632-85-9; 5,7-Dihydroxy-8-methoxyflavone; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-; 5,7-Dihydroxy-8-methoxy-2-phenyl-4H-chromen-4-one; Norwogonin 8-methyl ether; 5,7-Dihydroxy-8-methoxy-2-phenylchromen-4-one
CAS No.:
632-85-9
Compound CID:
5281703
Formula:
C16H12O5
Formula Weight:
284.26
Specification
Relative Density:
1.42 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Wogonin can be used in studies of neuroprotective effects or play an important role in the assessment of anti-inflammatory activity.
Library Information
Targets:
Wnt/beta-catenin; CDK
Receptors:
CDK8; Wnt
Pathways:
Autophagy; Cell cycle/Checkpoint; Stem cells; Apoptosis; Cytoskeletal signaling
Plate Number:
AOCL-4
Plate Location:
h6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 175.9 mM
Ethanol Max Solubility:
3 mg/mL; 10.55 mM
